We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In recent years, a range of advanced therapies have been ...
AbbVie ABBV announced that it is in-licensing exclusive global rights to develop and commercialize FG-M701, a next-generation TL1A antibody for the treatment of inflammatory bowel disease (IBD), from ...
AbbVie ABBV announced that it has acquired Celsius Therapeutics, a private biotech making novel therapies for treating inflammatory bowel diseases (“IBD”). The acquisition will add Celsius ...
Please provide your email address to receive an email when new articles are posted on . In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the potential of tumor necrosis factor-like ...
AbbVie has become the latest Big Pharma to jump on the anti-TL1A train, paying China’s FutureGen Biopharmaceutical $150 million upfront for a preclinical inflammatory bowel disease (IBD) candidate.
Good morning or good afternoon all, and welcome to the Duvakitug Anti-TL1A Phase 2b Data Presentation from ECCO. My name is Adam and I'll be your operator today. [Operator Instructions] I will now ...
ACG 2025 Immune Checkpoint Inhibitors Linked to Colon Adenoma Risk Patients who develop ICI-related diarrhea and colitis show an increased risk of developing colon adenomas, potentially compounding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results